Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

10.34 -0.88 (-7.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,598,490
Open 11.16
Bid (Size) 10.31 (2)
Ask (Size) 10.33 (1)
Prev. Close 11.22
Today's Range 10.33 - 11.25
52wk Range 7.705 - 21.59
Shares Outstanding 68,762,960
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 No-Brainer Stocks to Buy Right Now for Less Than $25
All three healthcare stocks are showing solid long-term potential. 
Via The Motley Fool
Why Editas Medicine's Shares Jumped This Week
The gene-editing biotech's shares have had a strong two-week run. 
Via The Motley Fool

Performance

YTD
+22.51%
+22.51%
1 Month
+25.79%
+25.79%
3 Month
-3.54%
-3.54%
6 Month
-44.26%
-44.26%
1 Year
-40.71%
-40.71%

More News

Read More
Is Editas Medicine Stock a Buy Now?
Via The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
Via InvestorPlace
Why Editas Medicine Stock Charged Higher in January
Via The Motley Fool
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Via Benzinga
Expert Ratings for Editas Medicine
Via Benzinga
Why Shares of Editas Medicine Jumped This Week
Via The Motley Fool
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
Analyst Expectations for Editas Medicine's Future
Via Benzinga
Why Editas Medicine Stock Is Sliding Today
Via The Motley Fool
Analyst Ratings for Editas Medicine
Via Benzinga
Why Shares of Editas Medicine Dropped 15.5% in November
Via The Motley Fool
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
From Editas Medicine, Inc.
Via Globe NewsWire
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
Via InvestorPlace
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
From Editas Medicine, Inc.
Via Globe NewsWire
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via Globe NewsWire
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
Via Benzinga
2 Beaten-Down Stocks to Watch Closely Next Year
Via The Motley Fool
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
Via Benzinga
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via Globe NewsWire
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.